EUVIMEDEUVIMED entdecken
Crossref

Investigating the C2 Modulation of the Imidazo[1,2‐ a ]pyrazine‐Based Hit Compound CTN1122: Synthesis, in vitro Antileishmanial Activity, Cytotoxicity and Casein Kinase 1 Inhibition

Lhana Tisseur, Sandrine Cojean iD, Khadidiatou Gassama, Cédric Logé iD, Fabrice Pagniez iD, Christian Cavé iD, Guillaume Bernadat iD, Philippe M Loiseau iD, Stéphane Bach iD, Jérôme Thiéfaine, Carine Picot iD, Christophe Tomasoni iD und 7 weitere

ChemMedChem · 2025

DOI: 10.1002/cmdc.202400862 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Lhana Tisseur und 18 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, Cibles et médicaments des infections et de l'immunité, IICiMed, UR 1155, F-44000, Nantes, France. Hauptthemen laut MEDLINE: Casein Kinase I, Antiprotozoal Agents, Pyrazines, Leishmania donovani. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our research group previously discovered CTN1122 , an imidazo[1,2‐ a ]pyrazine compound with promising antileishmanial activity against intramacrophage amastigotes of Leishmania major and L. donovani strains. CTN1122 effectively targets Leishmania casein kinase 1 (L–CK1.2) and exhibits a favorable safety profile. To further explore its chemical space, we developed a convergent strategy to modify the C2 position of the imidazo[1,2‐ a ]pyrazine core using Suzuki‐Miyaura coupling of the corresponding triflate intermediate. Among 15 newly synthesized analogs, seven derivatives featuring variously substituted phenyl rings at C2 demonstrated L–CK1.2 inhibition within micromolar to submicromolar ranges and antileishmanial activity in vitro with low cytotoxicity in macrophages. Compounds 7 d and 7 l were particularly potent, with IC 50 values of 1.25 μM and 0.92 μM against L. major , and 1.44 μM and 2.34 μM against L. donovani , respectively. They showed IC 50 L–CK1.2=0.30 μM and 0.57 μM with enhanced selectivity indices (SI=3.8 and 1.6) over the human CK1ϵ ortholog. Additionally, four C2 analogs and two C5 isomers exhibited notable antiparasitic effects without strongly inhibiting L–CK1.2, indicating a possible alternative mechanism of action. Compound 7 k displayed the highest general activity, with IC 50 values of 0.31 μM on L. major and 0.27 μM on L. donovani , coupled with favorable selectivity indexes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Casein Kinase IAntiprotozoal AgentsPyrazinesLeishmania donovaniProtein Kinase InhibitorsLeishmania majorImidazolesStructure-Activity RelationshipAnimalsMolecular StructureDose-Response Relationship, DrugMacrophagesParasitic Sensitivity TestsHumansMice

Stichwörter der Autor:innen

L–CK1.2 inhibitorsSuzuki–Miyaura coupling of heterocyclic triflatesantileishmanial agentscasein kinase 1imidazo[1,2-a]pyrazine

Substanzen

Casein Kinase IAntiprotozoal AgentsPyrazinesProtein Kinase InhibitorsImidazolesimidazo(1,2-a)pyrazine

Autor:innen und Institutionen

  • Nantes Université, Cibles et médicaments des infections et de l'immunité, IICiMed, UR 1155, F-44000, Nantes, France.
  • UMR BIPAR, Laboratory of Animal Health, Anses, INRAe, EnvA, F-94700, Maisons-Alfort, France.
  • Université Paris-Saclay, Faculté de Pharmacie, F-91400, Orsay, France.
  • Université Paris-Saclay, Chimiothérapie Antiparasitaire, Biomolécules : Conception, Isolement, Synthèse - BioCIS UMR CNRS 8076, F-91400, Orsay, France.
  • Sorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2 M), Station Biologique de Roscoff, 29680, Roscoff, France.
  • Sorbonne Université, CNRS, FR2424, Plateforme de criblage KISSf (Kinase Inhibitor Specialized Screening facility), Station Biologique de Roscoff, 29680, Roscoff, France.

ORCID-Profile: Sandrine Cojean, Cédric Logé, Fabrice Pagniez, Christian Cavé, Guillaume Bernadat, Philippe M Loiseau, Stéphane Bach, Carine Picot, Christophe Tomasoni, Olivier Leclercq, Blandine Baratte, Thomas Robert, Patrice Le Pape, Najma Rachidi, Marc-Antoine Bazin, Pascal Marchand

Zitieren

APA

Tisseur, L., Cojean, S., Gassama, K., Logé, C., Pagniez, F., Cavé, C., Bernadat, G., Loiseau, P. M., Bach, S., Thiéfaine, J., Picot, C., Tomasoni, C., Leclercq, O., Baratte, B., Robert, T., Le Pape, P., Rachidi, N., Bazin, M. A., & Marchand, P. (2025). Investigating the C2 Modulation of the Imidazo[1,2‐ a ]pyrazine‐Based Hit Compound CTN1122: Synthesis, in vitro Antileishmanial Activity, Cytotoxicity and Casein Kinase 1 Inhibition. ChemMedChem. https://doi.org/10.1002/cmdc.202400862

Vancouver

Tisseur L, Cojean S, Gassama K, Logé C, Pagniez F, Cavé C, et al. Investigating the C2 Modulation of the Imidazo[1,2‐ a ]pyrazine‐Based Hit Compound CTN1122: Synthesis, in vitro Antileishmanial Activity, Cytotoxicity and Casein Kinase 1 Inhibition. ChemMedChem. 2025. doi:10.1002/cmdc.202400862

BibTeX
@article{Tisseur2025,
  author = {Tisseur, Lhana and Cojean, Sandrine and Gassama, Khadidiatou and Logé, Cédric and Pagniez, Fabrice and Cavé, Christian and Bernadat, Guillaume and Loiseau, Philippe M and Bach, Stéphane and Thiéfaine, Jérôme and Picot, Carine and Tomasoni, Christophe and Leclercq, Olivier and Baratte, Blandine and Robert, Thomas and Le Pape, Patrice and Rachidi, Najma and Bazin, Marc-Antoine and Marchand, Pascal},
  title = {Investigating the C2 Modulation of the Imidazo[1,2‐ a ]pyrazine‐Based Hit Compound CTN1122: Synthesis, in vitro Antileishmanial Activity, Cytotoxicity and Casein Kinase 1 Inhibition},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202400862}
}
Kostenlos starten →